Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 10k
25 June 2020
E-003764/2020
Question for written answer
to the Commission
Rule 138
Jordi Cañas (Renew)
 Answer in writing 
 Subject: Additional funding for research on Myalgic Encephalomyelitis (ME/CFS)

On 18 June 2020, the European Parliament adopted Resolution 2020/2580(RSP) on additional funding for biomedical research on Myalgic Encephalomyelitis (ME/CFS) with the aim of developing and validating a biomedical diagnositic test and effective treatment that can cure the disease or alleviate its effects.

The lack of biomedical research and coordination regarding this chronic disease, which affects women in particular, poses the main obstacle for people suffering from the disease, since it is not known what causes it nor are there any recognised diagnostic or treatment protocols. Moreover, this group is particularly vulnerable to COVID-19 and experts consider that the number of sufferers may increase significantly as a result of the pandemic (1) .

In light of the above:

1. How does the Commission intend to ensure funding for research into ME/CFS through the Horizon Europe and EU4Health programmes?

2. Will the Commission put forward a proposal for the funding of research into diseases of unknown cause and rare diseases through a specific fund dedicated to their diagnosis, prevention and treatment?

(1)https://www.omf.ngo/2020/04/26/tracking-covid-19-patients
Original language of question: ES
Last updated: 13 July 2020Legal notice - Privacy policy